Medigene secures SynCore as global partner for EndoTAG-1

2 June 2013

German biotech firm Medigene (MDG: GR) has secured SynCore Biotechnology (part of Taiwan’s Sinphar Pharmaceutical Group) as a strategic (6%) investor and now global partner for EndoTAG-1, an extension of its July 2012 deal for Asian rights to the compound. A global Phase III study of EndoTAG-1 in triple negative breast cancer is expected to start in first-half 2014.

The deal removes prior uncertainty over EndoTAG’s future, say analysts at Edison Investment Research, who have raised their probability of success for EndoTAG-1 from 35% to 50%. Adding the 2.4 million euros ($3.0 million) upfront from SynCore’s purchase of 2.4 million new MediGene shares, their overall valuation increases to 85 million euros, or 2.15 euros per share.

EndoTAG-1 can now advance

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK